Evidence map›Paper›PMID 36224764›Full record

ArticleJournal of microbiology and biotechnology2022

Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein.

Yong-Fei Zhou, Jiao-Jiao Nie, Chao Shi, Ke Ning, Yu-Feng Cao, Yanbo Xie, Hongyu Xiang, Qiuhong Xie

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yong-Fei ZhouNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Jiao-Jiao NieNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Chao ShiNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Ke NingNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Yu-Feng CaoImmune-Path Biotechnology (Suzhou) Co., Ltd., Suzhou 215000, P.R. China.
Yanbo XieJilin Provincial Key Laboratory of Agricultural Biotechnology, Jilin Academy of Agricultural Sciences, Changchun 130033, P.R. China.
Hongyu XiangNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Qiuhong XieNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin 130012, P.R. China.
Jilin University · CNJilin Academy of Agricultural Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is an emerging disease that poses a severe threat to global public health. As such, there is an urgent demand for vaccines against SARS-CoV-2, the virus that causes COVID-19. Here, we describe a virus-like nanoparticle candidate vaccine against SARS-CoV-2 produced by an

Indexed as

COVID-19Hepatitis E virusViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsCOVID-19 VaccinesEscherichia coliHumansMiceMice, Inbred BALB CRecombinant ProteinsSARS-CoV-2Spike Glycoprotein, CoronavirusViral ProteinsAntibodies, NeutralizingAntibodies, ViralCapsid ProteinsCOVID-19 VaccinesORF2 protein, Hepatitis E virusRecombinant ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral ProteinsViral Vaccineshepatitis E virusrecombinant vaccineSARS-CoV-2virus-like nanoparticles

Identifiers

PMID36224764
PMCPMC9668089
OpenAlexW4304816528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.